Clinical trial
A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib…
NCT00480584 · H. Lee Moffitt Cancer Center and Research Institute, Other · Completed
Key facts
| NCT number | NCT00480584 |
|---|---|
| Title | A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer |
| Official title | A Phase I Trial of GemCap-T, Capecitabine in Combination With Gemcitabine and Erlotinib (Tarceva®) in Patients With Advanced Pancreatic Adenocarcinoma |
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Metastatic Pancreatic Carcinoma |
| Intervention type | Drug |
| Interventions | gemcitabine, capecitabine, erlotinib |
| Enrollment | 20 |
| Start date | Apr 1, 2007 |
| Primary completion | Nov 1, 2012 |
| Completion | Nov 1, 2012 |
| First posted | May 31, 2007 |
| Last update posted | Nov 8, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: